NASDAQ$KRRO
Korro Bio Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Announced business updates and financial results.
Frequency Therapeutics reported its Q3 2022 financial results, including a cash position of $99.3 million. The company completed enrollment for the Phase 2b study of FX-322 and is on track for a Q4 clinical trial start of FX-345. A multiple sclerosis remyelination program candidate was advanced to IND-enabling studies.
- Enrollment completed for Phase 2b study of FX-322, with readout expected in Q1 2023.
- Company on track for Q4 clinical trial start of its second hearing restoration program, FX-345.
- Multiple Sclerosis Remyelination Program Candidate Advanced to IND-Enabling Studies, with Anticipated 2H 2023 IND Filing.
- Cash, cash equivalents and marketable securities as of September 30, 2022, were $99.3 million.
Headline financials
Revenue & EPS history
Korro Bio · Revenue · Quarterly
$0
Forward guidance
Frequency Therapeutics believes its existing cash, cash equivalents and marketable securities will be sufficient to fund its operations into 2024.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
-4.6%
Avg return
Earnings day
+4.3%
Avg return
5 days after
+1.9%
Avg return
30 days after
43%
10 / 23 earnings
Positive
+20.6%
Q4 2023
Best reaction
-79.3%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.3% | -16.3% | -20.5% | |
| Q4 2025 | -0.4% | +14.5% | +20.4% | |
| Q3 2025 | -79.3% | -80.2% | -73.8% | |
| Q1 2025 | +4.1% | -2.0% | -11.8% | |
| Q4 2024 | -5.3% | -5.7% | -1.6% | |
| Q3 2024 | -25.2% | -35.3% | -40.2% | |
| Q2 2024 | +10.4% | +22.1% | +12.4% | |
| Q1 2024 | +5.0% | +8.8% | -15.4% | |
| Q4 2023 | +20.6% | +22.6% | -20.3% | |
| Q3 2023 | +9.4% | +192.6% | +246.3% | |
| Q2 2023 | -4.1% | -1.4% | -39.0% | |
| Q1 2023 | -5.6% | +6.2% | +1.9% | |
| Q4 2022 | +3.1% | -2.4% | -24.2% | |
| Q3 2022 | -5.8% | +4.4% | -11.1% | |
| Q2 2022 | -11.1% | -10.7% | -4.9% | |
| Q1 2022 | +4.0% | +1.6% | -8.0% | |
| Q3 2021 | +3.2% | -3.5% | -17.0% | |
| Q2 2021 | +0.5% | -9.9% | -12.3% | |
| Q1 2021 | -20.3% | -14.6% | -4.6% | |
| Q3 2020 | -6.4% | +4.6% | +59.7% | |
| Q2 2020 | -1.7% | -4.2% | -19.8% | |
| Q1 2020 | -1.1% | +5.1% | +16.0% | |
| Q3 2019 | +4.8% | +3.6% | +11.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro